Clover Biopharmaceuticals, Ltd.
Research Clover Biopharmaceuticals, Ltd. (2197.HK) on Bullrun: market cap HKD 2.00B, P/E 2.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2197.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 2.00B
- P/E2.1
- Financial periodFY2025
- RevenueCNY 3.51M
- Revenue growth-90.9%
- Net income-CNY 205.09M
- Free cash flow-CNY 194.86M
- Gross margin78.2%
Valuation Snapshot
latest market cap is HKD 2.00B; P/E is 2.1.
Peer valuation comparison
Latest P/E is 2.08x versus a Healthcare sector median of 21.69x (90.4% below).
Latest P/E is 2.08x versus a China median of 16.26x (87.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 3.51M | -CNY 205.09M | -CNY 194.86M | 78.2% | -0.16 | CNY 267.63M | CNY 10.61M | -CNY 1.80B |
| FY2024 | CNY 38.42M | -CNY 903.43M | -CNY 290.11M | 56.2% | -0.72 | CNY 401.24M | CNY 89.64M | -CNY 1.64B |
| FY2023 | CNY 39.26M | -CNY 138.54M | -CNY 737.05M | 61.8% | -0.11 | CNY 735.86M | CNY 334.45M | -CNY 732.83M |
| FY2022 | CNY 0 | -CNY 2.45B | -CNY 1.80B | n/a | -2.22 | CNY 1.61B | CNY 354.37M | -CNY 668.14M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 2.00B | 2.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Clover Biopharmaceuticals, Ltd.
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company's product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza; and SCB-219M, a thrombocytopenia receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Clover Biopharmaceuticals, Ltd.'s market cap?
Clover Biopharmaceuticals, Ltd.'s market capitalization is HKD 2.00B.
What is Clover Biopharmaceuticals, Ltd.'s P/E ratio?
Clover Biopharmaceuticals, Ltd.'s price-to-earnings (P/E) ratio is 2.1.
What does Clover Biopharmaceuticals, Ltd. do?
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company's product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza; and SCB-219M, a thrombocytopenia receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia.